A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 May 2017
At a glance
- Drugs PDA 002 (Primary)
- Indications Peripheral neuropathies
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 23 May 2017 Planned End Date changed from 1 Dec 2017 to 6 Nov 2017.
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2016 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.